Advertisement|Remove ads.

Shares of AstraZeneca Pharma India, Max Healthcare, Manappuram Finance, Muthoot Finance and JK Cement have touched fresh 52-week highs in June, driven by sectoral tailwinds, operational milestones, and regulatory developments, according to SEBI-registered analyst Mayank Singh Chandel.
Advertisement|Remove ads.
Manappuram Finance, which reported a fourth quarter (Q4) net loss of ₹203 crore due to stress in its Asirvad unit, rallied more than 50% over the past six months.
Chandel attributed the move to improved sector sentiment following the Reserve Bank of India’s relaxation of gold loan norms and a recent CEO appointment.
Advertisement|Remove ads.
AstraZeneca Pharma India advanced more than 30% in the past month and over 60% year-to-date, after reporting a 48% year-on-year rise in Q4 net profit and crossing ₹1,700 crore in FY25 revenue.
Chandel said the company is seeing robust growth in oncology and rare disease therapies.
Advertisement|Remove ads.
Max Healthcare also extended gains to fresh highs after posting a 15% year-over-year increase in quarterly revenue to around ₹1,800 crore.
Chandel cited strong operational delivery and NCR-focused expansion as key drivers.
Advertisement|Remove ads.
Muthoot Finance, up nearly 47% over the past year, benefited from RBI policy changes favouring gold loan providers.
The company reported Q4 revenue of approximately ₹3,250 crore and net profit of ₹1,444 crore.
Chandel noted stable profit margins and rising customer reach as support factors.
Advertisement|Remove ads.
JK Cement gained over 14% in June, with Q4 revenue of ₹3,100 crore and net profit of ₹361 crore.
Chandel said that the company’s capacity expansion and margin improvement have supported the rally.
Advertisement|Remove ads.
The analyst said these stocks show momentum backed by solid narratives and macro tailwinds.
For updates and corrections, email newsroom[at]stocktwits[dot]com.
Comments posted here will also appear on symbol pages.